Clinical studies have confirmed that increased expression of CXCL8 is linked with tumor development, suggesting that suppression of ELR-CXC chemokines may be an important therapeutic approach for aggressive and metastatic tumors. Here, CXCL8 is linked to metastatic neoplasm.